These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 23183440

  • 21. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
    Cook PP, Stang AT, Walker LR, Akula SM, Cook FJ.
    South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
    Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W, ONCEMRK Study Group.
    J Acquir Immune Defic Syndr; 2018 Aug 15; 78(5):589-598. PubMed ID: 29771789
    [Abstract] [Full Text] [Related]

  • 24. Role of raltegravir in HIV-1 management.
    Rokas KE, Bookstaver PB, Shamroe CL, Sutton SS, Millisor VE, Bryant JE, Weissman SB.
    Ann Pharmacother; 2012 Apr 15; 46(4):578-89. PubMed ID: 22496475
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, Ebrahimi R, McColl D, Kearney B, Fisher A, Flaherty J, BATON Study Group.
    HIV Clin Trials; 2008 Apr 15; 9(4):213-24. PubMed ID: 18753116
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group.
    Lancet; 2013 Mar 02; 381(9868):735-43. PubMed ID: 23306000
    [Abstract] [Full Text] [Related]

  • 29. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):163-74. PubMed ID: 19357529
    [Abstract] [Full Text] [Related]

  • 30. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.
    HIV Clin Trials; 2014 Jun 01; 15(5):218-30. PubMed ID: 25350960
    [Abstract] [Full Text] [Related]

  • 31. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
    Ortu F, Weimer LE, Floridia M, Manconi PE.
    Eur J Med Res; 2010 Feb 26; 15(2):81-3. PubMed ID: 20452889
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA.
    AIDS; 2007 Nov 12; 21(17):2315-21. PubMed ID: 18090280
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):535-40. PubMed ID: 17057609
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA, Jennings HC, Taylor C, Pakes GE, Acosta EP.
    HIV Clin Trials; 2009 Dec 15; 10(3):160-7. PubMed ID: 19632955
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.